Relief Therapeutics Holding (XSWX:RLF) Asset Impairment Charge : CHF40.02 Mil (TTM As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Relief Therapeutics Holding Asset Impairment Charge?

Relief Therapeutics Holding's Asset Impairment Charge for the six months ended in Jun. 2024 was CHF-0.01 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2024 was CHF40.02 Mil.

Relief Therapeutics Holding Asset Impairment Charge Historical Data

The historical data trend for Relief Therapeutics Holding's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Asset Impairment Charge Chart

Relief Therapeutics Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

11.20

-11.15

0.47

26.00

95.86

Relief Therapeutics Holding Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Asset Impairment Charge	Get a 7-Day Free Trial															7.85	18.15	55.83	40.03	-0.01

Relief Therapeutics Holding Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF40.02 Mil.

Relief Therapeutics Holding Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Relief Therapeutics Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (XSWX:RLF) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

RLFTY:USA RLFTF:USA RLFz:UK 0QKQ:UK

Address

Avenue de Secheron 15, Geneva, CHE, 1202

Website

https://www.relieftherapeutics.com

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development such as RLF-TD011, and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast among others. Geographically the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.

Relief Therapeutics Holding Headlines

No Headlines